Wegovy vs. Medicaid: States Rethink Obesity Drug Coverage
Update: 2025-10-21
Description
Wegovy vs. Medicaid: States are rethinking coverage for Novo Nordisk’s blockbuster obesity drug as costs skyrocket, leaving millions of low-income Americans at risk of losing access to this potentially life-changing treatment. Will states prioritize immediate budget concerns or long-term health benefits? The battle is on.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel